Trial Profile
PHASE II TRIAL OF SUNITINIB IN PATIENTS WITH TYPE B3 THYMOMA OR THYMIC CARCINOMA IN SECOND AND FURTHER LINES (STYLE Trial)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Malignant thymoma; Thymic epithelial tumour; Thymoma
- Focus Therapeutic Use
- Acronyms Style; Style Trial
- 22 Apr 2023 Results (n=44) published in the Journal of Thoracic Oncology
- 09 Aug 2022 Results (n=44) presented at the 2022 World Conference on Lung Cancer
- 08 Jun 2021 Planned End Date changed from 2 Mar 2021 to 31 May 2022.